^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Puyouheng (pucotenlimab)

    i
    Other names: HX008, HX 008, HX-008
    Company:
    HanX Biopharma, Lepu Med, Taizhou Hanzhong Biopharma
    Drug class:
    PD1 inhibitor
    Related drugs:
    22h
    Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=38, Not yet recruiting, Fudan University
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    1d
    Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sir Run Run Shaw Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    3d
    Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC (clinicaltrials.gov)
    P2, N=21, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Fumena (vorolanib)
    5d
    MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, West China Hospital
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    8d
    Clinical Efficacy of Pucotenlimab Combined with Lenvatinib and SOX Versus SOX Alone in Patients with HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Center Randomized Controlled Trial (ChiCTR2600116583)
    P=N/A, N=100, Not yet recruiting, Department of Gastric Surgery, Fujian Medical University Union Hospital; Fujian Medical University Union Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Lenvima (lenvatinib) • oxaliplatin • Puyouheng (pucotenlimab)
    8d
    Efficacy and Safety of Becotatug Vedotin (EGFR ADC) plus Pucotenlimab and Cisplatin as Neoadjuvant Therapy for LA-HNSCC (ChiCTR2600115972)
    P=N/A, N=30, Not yet recruiting, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    8d
    Pucotenlimab Combined with Lenvatinib and eribulin in Patients with Advanced Melanoma Failed in First-Line Therapy, a Single-Arm, Open-Label, Multicenter, Phase II Clinical Study (ChiCTR2500114916)
    P=N/A, N=35, Not yet recruiting, Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital
    New trial
    |
    Lenvima (lenvatinib) • irinotecan • Halaven (eribulin mesylate) • Puyouheng (pucotenlimab)
    8d
    Pucotenlimab Combined with Lenvatinib and eribulin in Patients with Advanced Sarcoma Failed in First-Line Therapy, a Single-Arm, Open-Label, Multicenter, Phase II Clinical Study (ChiCTR2500115523)
    P2, N=33, Not yet recruiting, Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital
    New P2 trial
    |
    Lenvima (lenvatinib) • irinotecan • Halaven (eribulin mesylate) • Puyouheng (pucotenlimab)
    12d
    LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study (clinicaltrials.gov)
    P1/2, N=10, Recruiting, Zhejiang Provincial People's Hospital | Phase classification: P=N/A --> P1/2 | N=20 --> 10
    Phase classification • Enrollment change
    |
    5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • Puyouheng (pucotenlimab)
    17d
    FUGES032: Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P1, N=100, Enrolling by invitation, Fujian Medical University
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Lenvima (lenvatinib) • oxaliplatin • Puyouheng (pucotenlimab) • Teysuno (gimeracil/oteracil/tegafur)
    17d
    PIONEER-HN: A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    docetaxel • Puyouheng (pucotenlimab) • TheraCIM (nimotuzumab)
    18d
    Magic-C002: A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P3, N=446, Recruiting, Shanghai Miracogen Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • docetaxel • capecitabine • Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)